Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07483099 · ClinicalTrials.gov registry record · Phase 2
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
A Phase 2 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07483099 is a Phase 2 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 60 participants.
The verdict
NCT07483099, a Phase 2 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.
Interventions
- DRUG Mirikizumab - Intravenous (IV)
- DRUG Mirikizumab - Subcutaneous (SC)
- DRUG LY4395089
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-05-04 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07483099
The ClinicalTrials.gov registry entry for NCT07483099 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Mirikizumab - Intravenous (IV) is the first listed.
NCT07483099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07483099 about?
NCT07483099 is a clinical study titled "A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease". The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protoco...
What is the current status of trial NCT07483099?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-05-04. Estimated completion is 2028-03.
What interventions are being tested in trial NCT07483099?
The interventions under investigation include: Mirikizumab - Intravenous (IV) (DRUG), Mirikizumab - Subcutaneous (SC) (DRUG), LY4395089 (DRUG).
Who is sponsoring clinical trial NCT07483099?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.